GNH USA

Europe — EMA

Orgalutran (Ganirelix)

GNH USA supplies Orgalutran (Ganirelix), a GnRH antagonist for preventing premature LH surge in controlled ovarian stimulation.

Ganirelix

Request sourcing

1
Pack/s

What is Ganirelix?

Ganirelix, the active ingredient in Orgalutran, is a GnRH antagonist presented as an injection solution for subcutaneous use. It prevents premature luteinizing hormone (LH) surge during controlled ovarian stimulation in assisted reproductive technology cycles.

GNH USA supplies Orgalutran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

What is Ganirelix used for?

Ganirelix is used in reproductive medicine to control the hormonal cascade during assisted reproductive technology. - Prevention of premature LH surge in controlled ovarian stimulation: suppresses the LH surge to allow timed egg retrieval. - Assisted reproductive technology (ART) cycles: facilitates synchronization of follicular development for optimal outcomes. - In vitro fertilization (IVF) protocols: improves control over ovulation timing and reduces risk of premature ovulation.

What are the side effects of Ganirelix?

Ganirelix may be associated with several adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Headache: transient headache reported by some patients. - Nausea: occasional mild nausea during treatment. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome: severe ovarian response requiring medical attention. - Allergic reaction (anaphylaxis): rare but potentially life‑threatening hypersensitivity. - Severe abdominal pain: intense pain that may indicate complications. - Thromboembolic events: rare clotting disorders requiring urgent care.

What precautions apply to Ganirelix?

When using Orgalutran, clinicians should observe several safety measures. - Dose adjustment: individualize based on ovarian response and monitoring results. - Monitoring: perform regular ultrasound and hormone assays throughout stimulation. - Allergy: assess for hypersensitivity to ganirelix or any excipients. - Pregnancy: not intended for use during established pregnancy; discontinue if pregnancy occurs. - Concomitant therapy: evaluate interactions with other hormonal agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Ganirelix interact with?

Ganirelix can interact with other medications; awareness of interaction severity is important.

Major Interactions (Avoid): - GnRH agonists: may counteract the antagonist effect and reduce efficacy. - High‑dose estrogen therapy: could diminish ganirelix suppression of LH surge. - Live vaccines: potential immunosuppression risk, though uncommon.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may affect overall hormonal balance during stimulation. - Anticoagulants: monitor for bleeding if ovarian hyperstimulation occurs. - Drugs affecting CYP enzymes: potential impact on ganirelix metabolism and plasma levels.

Frequently asked questions

What is Orgalutran used for?+
Orgalutran is used in assisted reproductive technology to prevent a premature luteinizing hormone (LH) surge during controlled ovarian stimulation. By suppressing the LH surge, it helps clinicians time egg retrieval more precisely, improving outcomes in in‑vitro fertilisation (IVF) and related fertility procedures.
How does Ganirelix work?+
Ganirelix is a competitive antagonist of gonadotropin‑releasing hormone (GnRH) receptors on the pituitary gland. By blocking GnRH binding, it rapidly reduces the secretion of LH and follicle‑stimulating hormone (FSH), thereby preventing the natural LH surge that would otherwise cause premature ovulation during ovarian stimulation.
What is the usual dose of Orgalutran?+
The specific dose of Orgalutran is determined by the treating physician based on the individual’s ovarian response, stimulation protocol, and monitoring results. Clinicians typically start with a standard dosing schedule and may adjust the amount or timing according to ultrasound and hormone measurements.
Is Ganirelix safe in pregnancy or breastfeeding?+
Ganirelix is not intended for use during an established pregnancy, and treatment is stopped if pregnancy is confirmed. Safety data for use while breastfeeding are limited; therefore, the medication is generally avoided during lactation unless the benefits outweigh potential risks as judged by a healthcare professional.
How do I order Orgalutran from GNH USA?+
To order Orgalutran, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.
How does Orgalutran compare with the main alternative drug or class?+
The primary alternative to Orgalutran is another GnRH antagonist, cetrorelix, which works by the same receptor‑blocking mechanism. Compared with GnRH agonists, antagonists like ganirelix provide a more immediate suppression of LH without the initial flare effect, allowing a shorter and more flexible stimulation protocol.
What are the storage and handling requirements for Orgalutran?+
Orgalutran should be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. It must not be frozen or shaken. If temporary temperature excursions occur, the product should be inspected for clarity and used only if it remains within specifications.
How is Orgalutran administered?+
Orgalutran is administered as a subcutaneous injection, typically in the abdominal wall or thigh. The injection is given once daily during the controlled ovarian stimulation phase, starting after the initial gonadotropin dose and continuing until the trigger for final oocyte maturation is administered.
What are the most serious risks to watch for with Orgalutran?+
The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can be severe and require hospitalization, and rare allergic reactions such as anaphylaxis. Patients should also be monitored for signs of thromboembolic events or severe abdominal pain, and any concerning symptoms should prompt immediate medical evaluation.
Who should not use Orgalutran?+
Orgalutran should be avoided in individuals with known hypersensitivity to ganirelix or any of its excipients. It is also contraindicated in patients with active ovarian cysts that could be exacerbated by stimulation, and it should not be used during an established pregnancy. Clinicians must assess each patient’s medical history before prescribing.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Ganirelix
Route
Subcutaneous Use
Manufacturer
N.V. Organon
Origin
EU

Related products

Astarté

Astarté

Ganirelix

Gp-Pharm S.A.
EU
Astarté

Astarté

Ganirelix

Gp-Pharm S.A.
EU
Fyremadel

Fyremadel

Ganirelix

Sun Pharmaceutical Industries Europe B.V.
EU
Fyremadel

Fyremadel

Ganirelix

Sun Pharmaceutical Industries Europe B.V.
EU